Daily Newsletter
Help us improve your experience, delivering more of what you want
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its first ESG report. The report details the Company’s commitment...
First Name
Last Name
Email address:
Add this web page on your home screen for quick and easy access when you’re on the go.